More recently, the research focus on DRAK2 has been renewed with studies demonstrating an important link between DRAK2 and non-alcoholic fatty liver disease (NAFLD) (Li et al., 2021). Here, STK17B is linked to metabolic dysfunction-associated steatotic liver disease.